Safety and tolerability of first‐line durvalumab with tremelimumab and chemotherapy in esophageal squamous cell carcinoma

Abstract Background Advanced or metastatic esophageal squamous cell carcinoma (ESCC) is associated with poor prognosis; new first‐line systemic treatment options are needed. Combining immuno‐oncology therapies with standard chemotherapy may represent a promising approach for the treatment of solid t...

Full description

Bibliographic Details
Published in:Cancer Medicine
Main Authors: Dae Ho Lee, Hye Ryun Kim, Bhumsuk Keam, Ken Kato, Yasutoshi Kuboki, Haiyan Gao, Alejandro Yovine, Scott H. Robbins, Myung‐Ju Ahn
Format: Article
Language:English
Published: Wiley 2023-08-01
Subjects:
chemotherapy
clinical trials
esophageal squamous cell
immunology
Online Access:https://doi.org/10.1002/cam4.6260

Internet

https://doi.org/10.1002/cam4.6260

Similar Items